Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Department of Labor Wants to Study Possible Occupation-Cancer Links

February 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

WASHINGTON--The US Department of Labor, Occupational Safety and Health Administration (OSHA) wants more money to study the possible associations between occupation and the incidence of cancer.

WASHINGTON--The US Department of Labor, Occupational Safety andHealth Administration (OSHA) wants more money to study the possibleassociations between occupation and the incidence of cancer.

Testifying before the President's Cancer Panel, Peter Infante,DDS, DrPH, director of OSHA's Office of Standards Review, saidthat OSHA needs the information to set the workplace standardfor permissible levels of certain substances believed to be carcinogens.

Dr. Infante said that 22 agents, proven carcinogenic by the WorldHealth Organization's International Agency for Research on Cancer(IARC), are still used in industry. In addition, 42 other industrialcompounds and agents are listed by the IARC as "probable"causes of human cancer on the basis of animal or epidemiologicevidence.

Articles in this issue

FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packages
Multidisciplinary Approach Urged For Pain Relief
FDA Approves New Indication for Neupogen: Chronic Neutropenia
Department of Labor Wants to Study Possible Occupation-Cancer Links
Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLC
ASH Panel: How Many Hemotologists/Oncologists Are Enough?
Mammography Van Brings Breast Cancer Screening to the Workplace
FDA to Build $600 Million Campus
Finasteride Studied as Prostate Ca Preventive
Panel Fails to Recommend Taxotere as Treatment for Breast and Lung Cancer
Thrombopoietin Raises Platelet Counts in Animals
Major Cancer Centers Form Network to Negotiate With Insurers
ACS Panel on Prostate Cancer: Painful Skeletal Mets Require Special Management
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
2 KOLs are featured in this series.
Related Content
Advertisement

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

Ariana Pelosci
September 16th 2025
Article

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


A statistically significant difference was observed between the 2 groups in patients who received second-line therapy.

Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC

Tim Cortese
September 16th 2025
Article

Cisplatin/etoposide and carboplatin/etoposide achieved median OSs of 8.8 months and 7.8 months, respectively, in those with extensive-stage small cell lung cancer.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


Understanding Palliative and End-Of-Life Care in Oncology

Understanding Palliative and End-Of-Life Care in Oncology

Julie M. Vose, MD, MBA
September 16th 2025
Article

Explore the vital role of palliative care in oncology, addressing misconceptions and enhancing patient support for better end-of-life experiences.


Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Russ Conroy
September 15th 2025
Article

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

Related Content
Advertisement

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

Ariana Pelosci
September 16th 2025
Article

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


A statistically significant difference was observed between the 2 groups in patients who received second-line therapy.

Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC

Tim Cortese
September 16th 2025
Article

Cisplatin/etoposide and carboplatin/etoposide achieved median OSs of 8.8 months and 7.8 months, respectively, in those with extensive-stage small cell lung cancer.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


Understanding Palliative and End-Of-Life Care in Oncology

Understanding Palliative and End-Of-Life Care in Oncology

Julie M. Vose, MD, MBA
September 16th 2025
Article

Explore the vital role of palliative care in oncology, addressing misconceptions and enhancing patient support for better end-of-life experiences.


Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Russ Conroy
September 15th 2025
Article

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.